CEO said, "we are undervalued". Okay, so how what is an approximate 'fair value' for LABS? Do we have any historical data to help us fairly value LABS? Not exactly but we do have a few data points at least that we know we are waiting on. Here's the data points I have if I had to value LABS fairly or at least in the same ball park.
1) FDA approval pending on the ANDA
2) FDA approval pending on the 505(b)2
So those are at least 2 new drugs for LABS and we know one of them is for a generic Epidiolex. And the other new drug we don't know yet. We also have a third data point.
3) JAZZ acquired GW Pharmaceuticals for $7.2 billion
That's about all I can think of as far as data points to help guide me in giving me some sort of direction of what fair market value would be for LABS when the 2 FDA approvals are granted.
We the ANDA and 505(b)2 approved and at $10 per share for LABS, we only have a market cap valuation of around $4.1 billion. That still looks like a bargain compared to GW.
......just so the newer and younger longs understand what you own.